Forex News
Teva Pharmaceuticals Presents Findings at Psych Congress
A single-source account says Teva Pharmaceuticals presented findings at Psych Congress; the discrete choice experiment included 489 HCP participants.
- Healthcare providers prioritized drowsiness risk, long-term response data duration and the drug-drug interaction profile.
- AUSTEDO had the highest predicted choice probability across all patient profiles.
- Among patients with untreated TD, 55%–69% reported stable or worsening TD severity.
Provider preferences
Teva Pharmaceuticals presented the findings at Psych Congress. The discrete choice experiment included 489 HCP participants.
Healthcare providers prioritized drowsiness risk, the duration of available data demonstrating long-term response, and the drug-drug interaction profile.
Choice probability
AUSTEDO® (deutetrabenazine) was closely related to the attributes valued by healthcare providers. Across all patient profiles, AUSTEDO had the highest predicted choice probability.
Patient burden
Among patients with untreated TD, 55%–69% reported stable or worsening TD severity.
In the IMPACT-TD Registry, 89%–96% of untreated TD patients experienced at least a mild global impact.